How Companion Diagnostics Enable Targeted Patient Stratification

Introduction: The Shift Toward Biomarker-Based Stratification

Companion diagnostics (CDx) are revolutionizing the clinical research and therapeutic landscape by enabling targeted patient stratification. No longer is a one-size-fits-all approach acceptable—biomarker-based stratification ensures patients receive therapies tailored to their genetic, proteomic, or molecular profiles. Whether in clinical trials or routine practice, stratification using CDx improves efficacy, reduces adverse effects, and accelerates regulatory approvals.

This article explores the strategic role of CDx in patient stratification, offering clinical examples, assay formats, and trial design frameworks that leverage predictive biomarker insights.

What Is Patient Stratification?

Patient stratification refers to the process of dividing a patient population into subgroups based on specific characteristics—commonly biomarkers, genetic mutations, or protein expression. The goal is to identify which subgroup is more likely to benefit from a given therapy.

• Predictive Biomarkers: Indicate likely response to therapy (e.g., HER2 for trastuzumab efficacy)
• Prognostic Biomarkers: Indicate disease outcome irrespective of treatment (e.g., BRCA1/2 in breast cancer)

Stratification ensures optimized therapeutic selection, enhancing the clinical trial’s statistical power and real-world outcomes.

Role of Companion Diagnostics in Stratification

Companion diagnostics are in vitro assays developed alongside therapeutics. Their role in stratification includes:

• Identifying biomarker-positive patients eligible for a targeted therapy
• Enabling enrichment strategies in clinical trials
• Reducing heterogeneity within treatment arms
• Ensuring regulatory compliance through validated predictive testing

FDA defines a CDx as a device that is essential for the safe and effective use of a corresponding therapeutic product. Its clinical relevance must be demonstrated through co-development with the drug.

Case Study: EGFR Mutation Testing in NSCLC

In non-small cell lung cancer (NSCLC), EGFR mutations (e.g., exon 19 deletions or L858R substitution) serve as predictive biomarkers for tyrosine kinase inhibitors (TKIs) like erlotinib or osimertinib. The cobas® EGFR Mutation Test v2 is an FDA-approved CDx for detecting these mutations.

Patient stratification using this test demonstrated:

• Increased progression-free survival (PFS) in biomarker-positive groups (9.6 months vs 5.2 months)
• Reduced treatment-related toxicities in off-target populations
• Higher trial success rate due to enriched enrollment

Such CDx-driven approaches underscore the power of precision medicine.

Clinical Trial Designs Incorporating Stratification

Clinical trial designs increasingly depend on CDx-based stratification:

• Enrichment Design: Includes only biomarker-positive patients
• Stratified Design: Includes all patients but stratifies randomization by biomarker status
• Adaptive Design: Modifies trial conduct based on interim biomarker response

Example Design Table:

Explore clinical validation approaches at PharmaValidation.in.

Examples of CDx-Enabled Patient Stratification

HER2 Testing in Breast Cancer: HER2 overexpression detected by IHC or FISH identifies candidates for trastuzumab or pertuzumab. Stratification improves outcomes and reduces cardiotoxicity in non-responders.

PD-L1 Expression in Immunotherapy: PD-L1 IHC assays help stratify patients likely to benefit from immune checkpoint inhibitors like pembrolizumab. Various CDx platforms (e.g., 22C3 pharmDx) have different cutoffs and scoring systems.

ALK Rearrangement in NSCLC: ALK-positive patients benefit from crizotinib. FISH-based CDx testing enables rapid identification and treatment decision-making.

In each of these cases, CDx-driven stratification leads to tailored therapy, faster trial recruitment, and reduced patient risk.

Validation of CDx for Stratification

Validation includes demonstrating analytical performance (LOD, LOQ, specificity) and clinical utility. A typical CDx validation dossier contains:

Proper validation ensures that stratification is based on reliable, reproducible data—essential for regulatory approval and patient safety.

Real-World Application of Stratification in Practice

In the post-approval phase, CDx-based stratification is implemented across clinical settings using standardized lab-developed tests (LDTs) or FDA/CE-approved kits. Challenges include:

• Inter-lab variability
• Turnaround time delays
• Cost and reimbursement variability
• Education of clinicians and patients

Despite these, the use of CDx in real-world stratification is expanding—especially with NGS platforms that assess multiple markers in parallel.

Regulatory guidance on stratification implementation is detailed in FDA guidance documents.

Future Trends in CDx-Based Stratification

Emerging trends include:

• Multi-marker Panels: Combining gene expression, mutation, and protein markers
• Liquid Biopsy: Non-invasive CDx testing from plasma ctDNA
• AI-Driven Stratification: Algorithms using real-world data to refine patient subgroups
• Platform-Based CDx: NGS and multiplex PCR-based stratification tools

For example, FoundationOne CDx provides genomic profiling across 300+ genes to stratify patients for over 30 targeted therapies.

Conclusion

Companion diagnostics have become indispensable tools for patient stratification in both clinical trials and routine care. Their ability to predict therapeutic response transforms treatment paradigms, improves patient outcomes, and accelerates drug development. As diagnostic technology advances, the precision and impact of stratification will only deepen—ushering in the next era of truly personalized medicine.